Aclarion, Inc. (NASDAQ:ACON) Short Interest Update

Aclarion, Inc. (NASDAQ:ACON) was the target of a significant increase in short interest in October. As of October 31st, there was short interest totalling 428,800 shares, an increase of 42.3% from the October 15th total of 301,400 shares. Based on an average daily trading volume, of 609,700 shares, the days-to-cover ratio is currently 0.7 days. Approximately 4.5% of the company’s stock are sold short.

Aclarion Price Performance

Shares of ACON stock opened at $0.17 on Friday. Aclarion has a 12 month low of $0.16 and a 12 month high of $7.40. The company’s fifty day simple moving average is $0.18 and its 200-day simple moving average is $0.25.

Aclarion (NASDAQ:ACON) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.04. Aclarion had a negative net margin of 10,967.15% and a negative return on equity of 910.84%. The firm had revenue of $0.01 million for the quarter. As a group, sell-side analysts forecast that Aclarion will post -0.86 EPS for the current year.

Institutional Trading of Aclarion

An institutional investor recently bought a new position in Aclarion stock. Virtu Financial LLC purchased a new stake in shares of Aclarion, Inc. (NASDAQ:ACON) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 115,183 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned about 1.40% of Aclarion as of its most recent filing with the Securities and Exchange Commission (SEC). 7.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets reissued a “buy” rating and issued a $1.50 target price (down previously from $1.60) on shares of Aclarion in a research report on Monday, August 26th.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.